Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
(2015) In Thrombosis Research 135(1). p.26-30- Abstract
- Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin). However, there are uncertainties regarding the risk for thrombosis since poor-responsiveness to clopidogrel is common. Ticagrelor is a more potent platelet inhibitor, but data supporting concurrent use of ticagrelor and warfarin (dual antithrombotic therapy, DT) is limited. This study therefore sought to evaluate the risk of bleeding and thrombosis associated with DT after an acute coronary syndrome (ACS).
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4912797
- author
- organization
-
- Cardiology
- Cardiovascular Research - Epidemiology (research group)
- Stem Cell Center
- Clinical Coagulation, Malmö (research group)
- Arrhytmias and Cardiac Device treatment (research group)
- Molecular Cardiology (research group)
- EXODIAB: Excellence of Diabetes Research in Sweden
- EpiHealth: Epidemiology for Health
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Thrombosis Research
- volume
- 135
- issue
- 1
- pages
- 26 - 30
- publisher
- Elsevier
- external identifiers
-
- pmid:25467434
- wos:000346432600006
- scopus:84922429372
- pmid:25467434
- ISSN
- 1879-2472
- DOI
- 10.1016/j.thromres.2014.10.016
- language
- English
- LU publication?
- yes
- id
- d0a6a5b9-fe96-40a0-bd07-daeada782295 (old id 4912797)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25467434?dopt=Abstract
- date added to LUP
- 2016-04-01 10:15:28
- date last changed
- 2022-08-27 07:47:08
@article{d0a6a5b9-fe96-40a0-bd07-daeada782295, abstract = {{Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin). However, there are uncertainties regarding the risk for thrombosis since poor-responsiveness to clopidogrel is common. Ticagrelor is a more potent platelet inhibitor, but data supporting concurrent use of ticagrelor and warfarin (dual antithrombotic therapy, DT) is limited. This study therefore sought to evaluate the risk of bleeding and thrombosis associated with DT after an acute coronary syndrome (ACS).}}, author = {{Braun, Oscar and Bico, Besim and Chaudhry, Uzma and Wagner, Henrik and Koul, Sasha and Tydén, Patrik and Scherstén, Fredrik and Jovinge, Stefan and Svensson, Peter and Smith, Gustav and vanderPals, Jesper}}, issn = {{1879-2472}}, language = {{eng}}, number = {{1}}, pages = {{26--30}}, publisher = {{Elsevier}}, series = {{Thrombosis Research}}, title = {{Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.}}, url = {{http://dx.doi.org/10.1016/j.thromres.2014.10.016}}, doi = {{10.1016/j.thromres.2014.10.016}}, volume = {{135}}, year = {{2015}}, }